Complex Generics Research
We have made significant progress in the development of our complex generics’ portfolio in FY20. Lupin R&D’s ongoing innovation in this category is a critical part of our strategy to bring a strong pipeline of complex generics products to the market. We launched our flagship inhalation product in the US Albuterol Sulphate in H2FY21. Lupin’s Albuterol MDI is the generic version of ProAir HFA and works as a key rescue inhalation product for asthma patients who are particularly vulnerable during COVID.
gFostair anchors our inhalation business in Europe and is expected to launch in the UK soon. In addition, our Netherlands subsidiary, Nanomi, has unique capabilities in the manufacture of microspheres and nanoparticles for the development of long acting injectables, based on its proprietary Microsieve technology. After a successful meeting with the U.S. FDA, Nanomi will soon embark on a clinical programme for its lead long-acting injectable asset.